Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

@article{Spear2011VascularDA,
  title={Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.},
  author={Matthew A. Spear and Patricia Lorusso and Alain C. Mita and Monica M. Mita},
  journal={Current drug targets},
  year={2011},
  volume={12 14},
  pages={
          2009-15
        }
}
Vascular Disrupting Agents (VDA) are a potential new class of oncology drugs that have garnered attention recently as a number of these agents have entered into Phase 2-3 studies. Currently available data suggest how the subsequent evolution of these agents into clinical practice may proceed, with new therapeutic paradigms based on similarities, differences and interactions with current standard of care agents. In particular, the broadly successful group of agents targeting angiogenesis through… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS